85P Phase II trial of tislelizumab plus sitravatinib as maintenance therapy in extensive-stage small-cell lung cancer (ES-SCLC)

Y. Fan, H. Li, K. Chen, L. Gong, Z. Huang, Y. Xu, X. Yu, G. Lou, H. Lu, W. Hong, J. Zhao,W. Wang, C. Gu, F. Xie, X. Xu, N. Han

Immuno-Oncology and Technology（2023）

Cited 0|Views1

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined